Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Crefmirlimab (Synonyms: 89Zr-Df-IAB22M2C)

Catalog No. T82670 Copy Product Info
🥰Excellent
Crefmirlimab (IAB22M2C) is a humanized anti-CD8 monoclonal antibody fragment (minibody) designed for PET imaging. Upon radiolabeling (e.g., with 89Zr), it serves as a non-invasive imaging biomarker that binds with high affinity and specificity to the CD8 receptor on CD8+ T cells, enabling real-time, dynamic tracking of T-cell distribution, infiltration, and trafficking in vivo in both preclinical models and clinical studies. It is a critical tool for evaluating the pharmacodynamics of T-cell engaging therapies (such as the GUCY2C-CD3 bispecific antibody PF-07062119) and for investigating the tumor immune microenvironment

Crefmirlimab

Copy Product Info
🥰Excellent
Catalog No. T82670
Synonyms 89Zr-Df-IAB22M2C

Crefmirlimab (IAB22M2C) is a humanized anti-CD8 monoclonal antibody fragment (minibody) designed for PET imaging. Upon radiolabeling (e.g., with 89Zr), it serves as a non-invasive imaging biomarker that binds with high affinity and specificity to the CD8 receptor on CD8+ T cells, enabling real-time, dynamic tracking of T-cell distribution, infiltration, and trafficking in vivo in both preclinical models and clinical studies. It is a critical tool for evaluating the pharmacodynamics of T-cell engaging therapies (such as the GUCY2C-CD3 bispecific antibody PF-07062119) and for investigating the tumor immune microenvironment

Crefmirlimab
Cas No. 2611099-93-3
Pack SizePriceUSA StockGlobal StockQuantity
1 mgInquiryInquiryInquiry
5 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Crefmirlimab (IAB22M2C) is a humanized anti-CD8 monoclonal antibody fragment (minibody) designed for PET imaging. Upon radiolabeling (e.g., with 89Zr), it serves as a non-invasive imaging biomarker that binds with high affinity and specificity to the CD8 receptor on CD8+ T cells, enabling real-time, dynamic tracking of T-cell distribution, infiltration, and trafficking in vivo in both preclinical models and clinical studies. It is a critical tool for evaluating the pharmacodynamics of T-cell engaging therapies (such as the GUCY2C-CD3 bispecific antibody PF-07062119) and for investigating the tumor immune microenvironment
In vitro
In cell-binding assays, Crefmirlimab (IAB22M2C) demonstrates high specificity and binding affinity for CD8 receptors expressed on human T cells, enabling sensitive detection and quantification of CD8+ populations without inducing significant T-cell activation or effector functions [1].
In vivo
In tumor-bearing mice, IV injection of radiolabeled Crefmirlimab (89Zr-Df-IAB22M2C) enables PET imaging to track the dynamic infiltration of CD8+ T cells into tumors and lymphoid organs. The study confirms its utility as a non-invasive biomarker for assessing therapeutic response and immune activation [1].
Synonyms89Zr-Df-IAB22M2C
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Uniprot ID
TargetCD8
Chemical Properties
Cas No.2611099-93-3
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Crefmirlimab | purchase Crefmirlimab | Crefmirlimab cost | order Crefmirlimab | Crefmirlimab in vivo | Crefmirlimab in vitro